Plasma biomarkers discriminate clinical forms of multiple sclerosis.

PLoS One · 2015 · PMC4454618 · PMID 26039252

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

In the test cohort, plasma EGF and MIP-1β/CCL4 statistically differed in both classification groups (p<0.0001 and p = 0.0002, respectively); in the validation cohort, both analytes showed a trend (p = 0.06) to be at lower concentrations in the plasma of progressive patients (SP-MS and PP-MS) than in RR-MS patients ( Table 3 ).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

We obtained a model that included the 4 analytes HGF, EGF, Eotaxin/CCL11 and MIP-1 β/CCL4) ( Table 4 ) as predictors for the MS-clinical form, while Rantes/CCL5 and MCP-1/CCL2 did not reach statistical significance to be included.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.